Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality -206% Improvement Relative Risk Hospitalization 79% Severe case 85% Severe case (b) 84% Time to sustained recovery -7% primary c19nitazoxanide.com Rossignol et al. NCT04486313 Nitazoxanide RCT EARLY Favors nitazoxanide Favors control
Rossignol, 379 patient nitazoxanide early treatment RCT: 79% lower hospitalization [p=0.22], 85% lower severe cases [p=0.07], and 7% slower recovery [p=0.88] https://c19p.org/rossignol
copied to clipboard
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
Rossignol et al., eClinicalMedicine, doi:10.1016/j.eclinm.2022.101310 (date from earlier preprint), NCT04486313 (history)
31 Mar 2021    Source   PDF   Share   Tweet
RCT with 184 outpatients treated with an extended release formulation of nitazoxanide, and 195 controls, showing lower hospitalization and progression to severe disease with treatment. There was one COVID-19 related death in the treatment arm. 600mg twice daily for five days. NCT04486313 (history).
risk of death, 206.0% higher, RR 3.06, p = 0.49, treatment 1 of 184 (0.5%), control 0 of 195 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), COVID-19 deaths.
risk of hospitalization, 78.8% lower, RR 0.21, p = 0.22, treatment 1 of 184 (0.5%), control 5 of 195 (2.6%), NNT 49.
risk of severe case, 84.9% lower, RR 0.15, p = 0.07, treatment 1 of 184 (0.5%), control 7 of 195 (3.6%), NNT 33.
risk of severe case, 83.9% lower, RR 0.16, p = 0.07, treatment 1 of 112 (0.9%), control 7 of 126 (5.6%), NNT 21, high-risk subgroup.
time to sustained recovery, 7.3% higher, relative time 1.07, p = 0.88, treatment 184, control 195, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rossignol et al., 31 Mar 2021, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 5 authors, study period August 2020 - February 2021, average treatment delay 1.83 days, trial NCT04486313 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit